用于预测癌症免疫疗法临床效果的免疫学生物标志物

• Format: Patent
• Language: Chinese
• Published: 20.06.2023
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

本发明涉及基于受试者的T细胞组成预测该受试者对癌症免疫疗法的响应性，以及基于该预测使用癌症免疫疗法的治疗方法。本发明还提供了改善或维持受试者对癌症免疫疗法的响应性的方法。通过测定与源自受试者的样品中抗肿瘤免疫应答的树突细胞刺激相关的CD4+T细胞亚群、树突细胞亚群和/或CD8+T细胞亚群的相对值来预测对癌症免疫疗法的响应性。还提供了用于治疗或预防癌症的组合物，其包含诸如CD62L低CD4+T细胞的细胞。 The present invention relates to the prediction of responsiveness to cancer immunotherapy of a subject based on the T-cell composition of the subject, and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining responsiveness to cancer immunotherapy of a subject. Responsiveness to cancer immunotherapy is predict by determining a relative value of a CD4+ T-cell subpopulation, dendritic cell subpopulation, and/or CD8+ T-cell subpopulation correlated with a dendritic cell stimulation in an anti-tumor immune response in a sample derived from a subject. A composition for treating or preventing cancer comprising cells such as CD62LlowCD4+T-cells is also provided.